Jim Delshad Buys 5,000 Shares of Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) Director Jim Delshad purchased 5,000 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average cost of $7.22 per share, for a total transaction of $36,100.00. Following the completion of the acquisition, the director now directly owns 55,310 shares of the company’s stock, valued at $399,338.20. This represents a 9.94% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Jim Delshad also recently made the following trade(s):

• On Wednesday, March 26th, Jim Delshad purchased 50 shares of Neonc Technologies stock. The shares were purchased at an average cost of $16.05 per share, for a total transaction of $802.50.
• On Thursday, April 17th, Jim Delshad purchased 50 shares of Neonc Technologies stock. The shares were purchased at an average cost of $6.92 per share, for a total transaction of $346.00.

Neonc Technologies Stock Down 2.4%

Shares of NASDAQ NTHI opened at $7.25 on Wednesday. Neonc Technologies Holdings, Inc. has a 1 year low of $4.11 and a 1 year high of $25.00.

Neonc Technologies (NASDAQ:NTHI) last announced its quarterly earnings results on Friday, May 9th. The company reported ($2.10) earnings per share (EPS) for the quarter. The company had revenue of $0.04 million for the quarter.

Hedge Funds Weigh In On Neonc Technologies

An institutional investor recently bought a new position in Neonc Technologies stock. HighPoint Advisor Group LLC acquired a new stake in shares of Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 21,672 shares of the company’s stock, valued at approximately $290,000.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing.